Immutep Announces Presentation of New TACTI-002 Data at the 2023 ASCO Annual Meeting

Rhea-AI Summary

Immutep Limited (ASX: IMM; NASDAQ: IMMP) announced the presentation of final results from the Phase II TACTI-002 trial, focusing on patients with second-line head and neck squamous cell carcinoma. The results will be showcased at the 2023 ASCO Annual Meeting, which takes place from June 2-6 in Chicago, Illinois. The trial evaluates the combination of eftilagimod alpha and pembrolizumab in patients who are unselected for PD-L1 expression. Additionally, the trial design for the Phase II/III AIPAC-003 study, which tests eftilagimod alpha in HER2-negative metastatic breast cancer, will also be presented. Key presentation details include poster sessions on June 4 and 5. This opportunity allows Immutep to engage with leading oncology experts and gain visibility for its innovative therapies.

Positive

• Presentation of final trial results at a major oncology conference enhances visibility.
• Potential to showcase innovative dual immunotherapy approach in a key patient demographic.

Negative

• None.

Media Release

Final results from Part C of the Phase II TACTI-002 trial in 2nd line head and neck squamous cell carcinoma patients to be presented

SYDNEY, AUSTRALIA, April 26, 2023 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces two abstracts have been selected for poster presentation at the upcoming 2023 American Society of Clinical Oncology’s (ASCO) Annual Meeting, taking place in-person and online from 2-6 June 2023 in Chicago, Illinois (United States).

New, final data from Part C of the Phase II TACTI-002 trial evaluating the investigational dual immuno-oncology combination of eftilagimod alpha and pembrolizumab in 2nd line head and neck squamous cell carcinoma patients unselected for PD-L1 expression will be presented. In addition, the Phase II/III AIPAC-003 trial design will be presented in a Trial-in-Progress Poster. Presentation details are as follows:

TACTI-002 (Part C) Poster
Title: Final results from TACTI-002 Part C: A Phase II study of eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab in patients with metastatic 2nd line head and neck squamous cell carcinoma unselected for PD-L1.
Poster Session: Head and Neck Cancer
Date and Time: 5 June 2023, 2:15PM-5:15PM EDT
Presenter: Dr. Bernard Doger, START Madrid-FJD, Fundación Jiménez Díaz University Hospital, Madrid, Spain
Abstract #: 6029

AIPAC-003 Poster
Title: AIPAC-003: A randomized, double-blind, placebo-controlled phase 3 trial testing eftilagimod alpha (soluble LAG-3) in HER2-neg/low metastatic breast cancer patients receiving paclitaxel, following an open-label dose optimization.
Poster Session: Breast Cancer – Local/Regional/Adjuvant
Date and Time: 4 June 2023, 9:00AM-12:00PM EDT
Presenter: Dr. Nuhad K. Ibrahim, Professor, Department of Breast Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Abstract #: TPS1120

Abstracts for the presentations will be available after 5:00PM US Eastern Time on 25 May 2023 on ASCO.org.

About ASCO 2023
ASCO’s annual meeting represents the world’s largest gathering of oncology physicians, industry representatives, researchers, patient advocates, and investment analysts to discuss cutting-edge clinical research and therapeutics in oncology, and to gain insights for improving cancer care. More than 40,000 attendees from around the world are expected to attend in person and online to stay up to date on new clinical cancer advances in every area of cancer research and gain real-time insights from world-renowned faculty. For additional information on the 2023 ASCO’s Annual meeting, please visit https://www.asco.org/.

About Immutep
Immutep is a clinical stage biotechnology company developing novel LAG-3 immunotherapy for cancer and autoimmune disease. We are pioneers in the understanding and advancement of therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), and our diversified product portfolio harnesses its unique ability to stimulate or suppress the immune response. Immutep is dedicated to leveraging its expertise to bring innovative treatment options to patients in need and to maximise value for shareholders. For more information, please visit www.immutep.com.

Australian Investors/Media:
Catherine Strong, Citadel-MAGNUS
+61 (0)406 759 268; cstrong@citadelmagnus.com

U.S. Media:
Chris Basta, VP, Investor Relations and Corporate Communications
+1 (631) 318 4000; chris.basta@immutep.com

 

FAQ

What is the significance of the TACTI-002 trial results for Immutep (IMMP)?

The TACTI-002 trial results are significant as they demonstrate the effectiveness of a dual immunotherapy approach in a specific cancer patient population, potentially impacting treatment options.

When and where will the Phase II TACTI-002 trial results be presented?

The results will be presented at the 2023 ASCO Annual Meeting in Chicago on June 5, 2023.

What is eftilagimod alpha and its role in Immutep's clinical trials?

Eftilagimod alpha is an investigational immunotherapy being tested in combination with pembrolizumab for cancer treatment in the TACTI-002 trial.

What does the AIPAC-003 trial involve?

The AIPAC-003 trial involves testing eftilagimod alpha in HER2-negative metastatic breast cancer patients receiving paclitaxel, aiming to further validate its therapeutic potential.